TY - JOUR
T1 - Role of human papillomavirus infection in head and neck cancer in Italy
T2 - The HPV-AHEAD study
AU - the HPV-AHEAD study group
AU - Tagliabue, Marta
AU - Mena, Marisa
AU - Maffini, Fausto
AU - Gheit, Tarik
AU - Blasco, Beatriz Quirós
AU - Holzinger, Dana
AU - Tous, Sara
AU - Scelsi, Daniele
AU - Riva, Debora
AU - Grosso, Enrica
AU - Chu, Francesco
AU - Lucas, Eric
AU - Ridder, Ruediger
AU - Rrehm, Susanne
AU - Bogers, Johannes Paul
AU - Lepanto, Daniela
AU - Rubio, Belén Lloveras
AU - Kumar, Rekha Vijay
AU - Gangane, Nitin
AU - Clavero, Omar
AU - Pawlita, Michael
AU - Anantharaman, Devasena
AU - Pillai, Madhavan Radhakrishna
AU - Brennan, Paul
AU - Sankaranarayanan, Rengaswamy
AU - Arbyn, Marc
AU - Lombardi, Francesca
AU - Taberna, Miren
AU - Gandini, Sara
AU - Chiesa, Fausto
AU - Ansarin, Mohssen
AU - Alemany, Laia
AU - Tommasino, Massimo
AU - Chiocca, Susanna
N1 - Funding Information:
This study was funded by European Commission HPV-AHEAD. Grant Number: FP7-HEALTH-2011?282562. This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5 ? 1000 funds. M. Ar. was supported by the Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network, Grant Number 847845. Research on HPV and Head and Neck Cancer in Susanna Chiocca laboratory was also supported by Associazione Italiana Ricerca sul Cancro (A.I.R.C. IG 2015 Id.16721).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Literature on the role of human papillomavirus (HPV) in head and neck cancer (HNC) in Italy is limited, especially for non-oropharyngeal tumours. Within the context of the HPV-AHEAD study, we aimed to assess the prognostic value of different tests or test algorithms judging HPV carcinogenicity in HNC and factors related to HPV positivity at the European Institute of Oncology. We conducted a retrospective cohort study (2000–2010) on a total of 696 primary HNC patients. Formalin-fixed, paraffin-embedded cancer tissues were studied. All HPV-DNA-positive and a random sample of HPV-DNA-negative cases were subjected to HPV-E6*I mRNA detection and p16INK4a staining. Multivariate models were used to assess for factors associated with HPV positivity and proportional hazards for survival and recurrence. The percentage of HPV-driven cases (considering HPV-E6*I mRNA positivity) was 1.8, 2.2, and 40.4% for oral cavity (OC), laryngeal (LC), and oropharyngeal (OPC) cases, respectively. The estimates were similar for HPV-DNA/p16INK4a double positivity. Being a non-smoker or former smoker or diagnosed at more recent calendar periods were associated with HPV-E6*I mRNA positivity only in OPC. Being younger was associated with HPV-E6*I mRNA positivity in LC. HPV-driven OPC, but not HPV-driven OC and LC, showed better 5 year overall and disease-free survival. Our data show that HPV prevalence in OPC was much higher than in OC and LC and observed to increase in most recent years. Moreover, HPV positivity conferred better prognosis only in OPC. Novel insights on the role of HPV in HNC in Italy are provided, with possible implications in the clinical management of these patients.
AB - Literature on the role of human papillomavirus (HPV) in head and neck cancer (HNC) in Italy is limited, especially for non-oropharyngeal tumours. Within the context of the HPV-AHEAD study, we aimed to assess the prognostic value of different tests or test algorithms judging HPV carcinogenicity in HNC and factors related to HPV positivity at the European Institute of Oncology. We conducted a retrospective cohort study (2000–2010) on a total of 696 primary HNC patients. Formalin-fixed, paraffin-embedded cancer tissues were studied. All HPV-DNA-positive and a random sample of HPV-DNA-negative cases were subjected to HPV-E6*I mRNA detection and p16INK4a staining. Multivariate models were used to assess for factors associated with HPV positivity and proportional hazards for survival and recurrence. The percentage of HPV-driven cases (considering HPV-E6*I mRNA positivity) was 1.8, 2.2, and 40.4% for oral cavity (OC), laryngeal (LC), and oropharyngeal (OPC) cases, respectively. The estimates were similar for HPV-DNA/p16INK4a double positivity. Being a non-smoker or former smoker or diagnosed at more recent calendar periods were associated with HPV-E6*I mRNA positivity only in OPC. Being younger was associated with HPV-E6*I mRNA positivity in LC. HPV-driven OPC, but not HPV-driven OC and LC, showed better 5 year overall and disease-free survival. Our data show that HPV prevalence in OPC was much higher than in OC and LC and observed to increase in most recent years. Moreover, HPV positivity conferred better prognosis only in OPC. Novel insights on the role of HPV in HNC in Italy are provided, with possible implications in the clinical management of these patients.
KW - Head and neck cancer
KW - Human papillomavirus
KW - Human papillomavirus diagnosis
KW - Oropharyngeal cancer
KW - Virus-related cancers
UR - http://www.scopus.com/inward/record.url?scp=85097397464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097397464&partnerID=8YFLogxK
U2 - 10.3390/cancers12123567
DO - 10.3390/cancers12123567
M3 - Article
AN - SCOPUS:85097397464
VL - 12
SP - 1
EP - 19
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 12
M1 - 3567
ER -